(OLMA) Olema Pharmaceuticals - Ratings and Ratios

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to advancing therapies for womens cancers, with a primary focus on estrogen receptor-positive (ER+) breast cancer. The companys lead product candidate, OP-1250, is an oral, non-steroidal estrogen receptor (ER) antagonist and selective ER degrader. It is currently in Phase 3 clinical trials for the treatment of recurrent, locally advanced, or metastatic ER+/HER2- breast cancer. Additionally, OP-1250 is being investigated in combination with CDK4/6 inhibitors (palbociclib, ribociclib, and alpelisib) in Phase 1/2 clinical trials for the same indication. The company is also developing OPERA-01, a clinical program targeting ER+/HER2- advanced or metastatic breast cancer. Olema Pharmaceuticals, formerly known as CombiThera, Inc., was incorporated in 2006, changed its name in March 2009, and is headquartered in San Francisco, California.

Based on the provided and , here is a 3-month forecast:

indicates that OLMA is currently trading at $4.41, below its 20-day SMA of $5.35 and 50-day SMA of $5.63, signaling bearish momentum. The stock is also significantly below its 200-day SMA of $10.21, suggesting a longer-term downtrend. The average trading volume of 833,231 shares over 20 days and an ATR of 0.46 indicate moderate volatility.

shows a market cap of $377.16M, with a price-to-book ratio of 1.93, indicating the stock is trading at nearly twice its book value. The return on equity (RoE) of -61.68% reflects significant losses. The absence of P/E and P/S ratios suggests the company is pre-revenue or in early-stage development.

Forecast: Over the next three months, OLMA is likely to face continued selling pressure, given its position below key moving averages. The stock may find resistance near $5.35 (SMA20) and $5.63 (SMA50), with potential support near $4.00. The negative RoE and lack of profitability could weigh on investor sentiment, potentially driving the stock lower unless positive clinical trial data or strategic developments emerge.